EXTH-52. EGFRvIII: A NEW PREDICTIVE BIOMARKER FOR TEMOZOLOMIDE RESPONSE IN MGMT PROMOTOR METHYLATED GLIOBLASTOMA PATIENTS

Despite many clinical efforts, the prognosis of GBM patients has not improved in the last 10 years. Epigenetic silencing of the O6-methylguanine-DNA-methyltransferase (MGMT) gene is the only predictive biomarker that is associated with temozolomide (TMZ) response. The establishment of new biomarkers...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Struve, Nina, Brend, Tim, Stead, Lucy, Binder, Zev A, Ott, Leonie, Muller-Goebel, Justus, Hoffer, Konstatin, Morrissette, Jennifer J D, Petersen, Cordula, Rothkamm, Kai, O’Rourke, Donald, Short, Susan C, Kriegs, Malte
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692225/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.344
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados